Abbott Laboratories (ABT) Maintains Strong MedTech Growth Outlook

Core Viewpoint - Abbott Laboratories (NYSE:ABT) is highlighted as a top choice for retirement portfolios, with UBS maintaining a Buy rating and a price target of $154, emphasizing confidence in the company's growth trajectory, particularly in its MedTech division which is expected to sustain growth rates of 10% or more [1][2]. Group 1: Company Performance - Abbott Laboratories is recognized as a leading global healthcare company that produces a diverse range of products including branded generic medications, medical devices, diagnostics, and nutritional items [3]. - UBS anticipates that Abbott will outperform competitors in margin expansion and earnings per share growth, with the stock currently trading at approximately 23 times the consensus earnings per share for 2026, which is a discount compared to the large-cap MedTech category averaging around 28 times projected earnings [2]. Group 2: Market Position - The MedTech division of Abbott is a focal point for future growth, with expectations of maintaining robust growth rates, contributing to the overall positive outlook for the company [1].